5-Feb-2024 | Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial | Brittain, G; Petrie, J; Duffy, KEM; Glover, R; Hullock, K; Papaioannou, D; Roldan, E; Beecher, C; Bursnall, M; Ciccarelli, O; Coles, AJ; Cooper, C; Giovannoni, G; Gabriel, I; Kazmi, M; Kyriakou, C; Nicholas, R; Paling, D; Peniket, A; Scolding, N; Silber, E; de Silva, T; Venneri, A; Walters, SJ; Young, C; Muraro, PA; Sharrack, B; Snowden, JA |